EU Regulators Clear Ozempic and Related Drugs of Suicidal Thoughts Link

After a comprehensive review, the European Medicines Agency confirms no causal link between GLP-1 drugs and increased suicidal ideation.

The European Medicines Agency concluded a nine-month investigation, finding no evidence that drugs like Ozempic and Wegovy increase the risk of suicidal thoughts.
Multiple studies, including large-scale electronic health records, support the safety of GLP-1 drugs concerning mental health risks.
Despite previous anecdotal reports, regulatory bodies will continue to monitor the drugs as part of ongoing pharmacovigilance activities.
The FDA's preliminary review aligns with the EMA's findings, though it mentions a small, unconfirmed risk still under investigation.
Patients are advised to report any mental health issues to healthcare providers as monitoring continues.